Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
Michael Gnant(Comprehensive Cancer Center Vienna), Martin Filipits(Comprehensive Cancer Center Vienna), Richard Greil(Paracelsus Medical University), Herbert Stoeger(Medical University of Graz), Margaretha Rudas(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Brigitte Mlineritsch(Paracelsus Medical University), W. Kwasny(State Hospital), Michael Knauer(Sisters of Charity Hospital), Christian F. Singer(Comprehensive Cancer Center Vienna), R. Jakesz(Comprehensive Cancer Center Vienna), Peter Dubsky(Comprehensive Cancer Center Vienna), Florian Fitzal(Comprehensive Cancer Center Vienna), Rupert Bartsch(Comprehensive Cancer Center Vienna), G. Steger(Comprehensive Cancer Center Vienna), Marija Balić(Medical University of Graz), Sigrun Ressler(Paracelsus Medical University), J. Wayne Cowens(Nanostring Technologies (United States)), James J. Storhoff(Nanostring Technologies (United States)), Sean Ferree(Nanostring Technologies (United States)), Carl Schaper, S. Liu(BC Cancer Agency), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Torsten O. Nielsen(BC Cancer Agency)
Cited by 399Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis